📊 ATNM Key Takeaways
Is Actinium Pharmaceuticals, Inc. (ATNM) a Good Investment?
Actinium Pharmaceuticals faces severe financial distress with near-total revenue collapse (97.4% YoY decline), massive operating losses (-$29.8M), and negative free cash flow (-$19.3M). Despite maintaining adequate liquidity, the company is burning cash rapidly with no apparent path to profitability, making this a highly distressed biotech with substantial going-concern risk.
Actinium Pharmaceuticals shows extremely weak current fundamentals, with revenue collapsing 97.4% year over year to just $90K and losses that remain very large relative to its asset and equity base. The balance sheet is helped by a strong cash position and low debt, but the business currently lacks operating scale, profitability, and self-funding capacity, making growth quality poor and execution risk very high.
Why Buy Actinium Pharmaceuticals, Inc. Stock? ATNM Key Strengths
- Strong liquidity position with $53.4M cash and 7.96x current ratio provides short-term runway
- Low leverage with 0.07x debt-to-equity ratio limits financial distress from debt obligations
- Minimal capital expenditure needs ($11K) suggest asset-light business model
- Strong near-term liquidity, with $53.39M in cash and current and quick ratios of 7.96x
- Low balance-sheet leverage, with only $900K of long-term debt and debt-to-equity of 0.07x
- Limited capital expenditure needs, which reduces fixed asset burden while management funds development
ATNM Stock Risks: Actinium Pharmaceuticals, Inc. Investment Risks
- Revenue essentially eliminated with only $90K in latest period, down 97.4% YoY indicating business collapse
- Massive operating losses of $29.8M and negative FCF of $19.3M indicate unsustainable cash burn with ~2.8 year runway at current burn rate
- Company is pre-revenue or post-revenue failure with -31,052% net margin and -202.7% ROE, showing fundamental business dysfunction
- Zero gross profit and near-total loss of revenue suggests failed commercialization or product withdrawal
- Revenue base is negligible and deteriorated sharply, down 97.4% year over year, indicating weak commercialization traction
- Operating and net losses are extremely large relative to revenue, assets, and equity, with ROE of -202.7% and operating margin of -33147.8%
- Negative operating cash flow and free cash flow of about $19.3M create ongoing financing risk if revenue does not scale materially
Key Metrics to Watch
- Monthly cash burn rate and cash runway to determine going-concern timeline
- Any pipeline advancement announcements or new revenue-generating partnerships
- Quarterly revenue and operating loss trends to assess if decline has stabilized or continuing deterioration
- Quarterly cash burn versus cash balance to assess runway durability
- Sustainable revenue growth and gross profit generation from commercialization or partnership activity
Actinium Pharmaceuticals, Inc. (ATNM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.96x current ratio provides a solid financial cushion.
ATNM Profit Margin, ROE & Profitability Analysis
ATNM vs Healthcare Sector: How Actinium Pharmaceuticals, Inc. Compares
How Actinium Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Actinium Pharmaceuticals, Inc. Stock Overvalued? ATNM Valuation Analysis 2026
Based on fundamental analysis, Actinium Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Actinium Pharmaceuticals, Inc. Balance Sheet: ATNM Debt, Cash & Liquidity
ATNM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Actinium Pharmaceuticals, Inc.'s revenue has declined by 92% over the 5-year period, indicating business contraction. The most recent EPS of $-1.27 indicates the company is currently unprofitable.
ATNM Revenue Growth, EPS Growth & YoY Performance
ATNM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $90.0K | -$5.1M | $-0.16 |
| Q3 2023 | $45.0K | -$5.1M | $-0.38 |
| Q2 2023 | $45.0K | -$5.1M | $-0.33 |
| Q1 2023 | $940.0K | -$5.1M | $-0.23 |
| Q3 2022 | $45.0K | -$5.0M | $-0.30 |
| Q2 2022 | $45.0K | -$5.0M | $-0.25 |
| Q1 2022 | $622.0K | -$5.1M | N/A |
| Q3 2021 | $233.0K | -$4.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Actinium Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ATNM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Actinium Pharmaceuticals, Inc. (CIK: 0001388320)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATNM
What is the AI rating for ATNM?
Actinium Pharmaceuticals, Inc. (ATNM) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATNM's key strengths?
Claude: Strong liquidity position with $53.4M cash and 7.96x current ratio provides short-term runway. Low leverage with 0.07x debt-to-equity ratio limits financial distress from debt obligations. ChatGPT: Strong near-term liquidity, with $53.39M in cash and current and quick ratios of 7.96x. Low balance-sheet leverage, with only $900K of long-term debt and debt-to-equity of 0.07x.
What are the risks of investing in ATNM?
Claude: Revenue essentially eliminated with only $90K in latest period, down 97.4% YoY indicating business collapse. Massive operating losses of $29.8M and negative FCF of $19.3M indicate unsustainable cash burn with ~2.8 year runway at current burn rate. ChatGPT: Revenue base is negligible and deteriorated sharply, down 97.4% year over year, indicating weak commercialization traction. Operating and net losses are extremely large relative to revenue, assets, and equity, with ROE of -202.7% and operating margin of -33147.8%.
What is ATNM's revenue and growth?
Actinium Pharmaceuticals, Inc. reported revenue of $90.0K.
Does ATNM pay dividends?
Actinium Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ATNM SEC filings?
Official SEC filings for Actinium Pharmaceuticals, Inc. (CIK: 0001388320) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATNM's EPS?
Actinium Pharmaceuticals, Inc. has a diluted EPS of $-0.90.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ATNM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Actinium Pharmaceuticals, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ATNM stock overvalued or undervalued?
Valuation metrics for ATNM: ROE of -202.7% (sector avg: 15%), net margin of -31,052.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ATNM stock in 2026?
Our dual AI analysis gives Actinium Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ATNM's free cash flow?
Actinium Pharmaceuticals, Inc.'s operating cash flow is $-19.3M, with capital expenditures of $11.0K. FCF margin is -21,446.7%.
How does ATNM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -31,052.2% (avg: 12%), ROE -202.7% (avg: 15%), current ratio 7.96 (avg: 2).